Nicox S.A. (NYSE Euronext Paris: COX) today reports financial results for the six months ended June 30, 2012, and provided an update on its activities.
Key highlights for the first half of 2012
· Worldwide in-licensing agreement with RPS® for innovative diagnostic tests in the ocular field, including
AdenoPlus™
· Management team strengthened with the appointments of Jerry St. Peter in the United States and Philippe
Masquida in Europe
· Positive phase 2b results observed with glaucoma candidate BOL-303259-X; Bausch + Lomb to move compound into phase 3 development program
· 11.8% investment in Altacor, a privately-held ophthalmology company based in the United Kingdom